Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL123936 | 0.99 | SMO (0.53) | SMORECQLPDE10AP2RX7NPC1 | |
| SCHEMBL172294 | 0.91 | SMO (0.58) | SMOPDE10ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL124141 | 0.90 | SMO (0.57) | SMOPDE10ANPC1RAB9A | |
| SCHEMBL172033 | 0.88 | PDE10A (0.46) | SMOPDE10AKMT2APDE2APDE1B | |
| Hydrochloric Acid SCHEMBL125078 | 0.87 | PDE10A (0.46) | SMOPDE10AKMT2APDE2APDE1B | |
| SCHEMBL171974 | 0.85 | GAA (0.43) | PDE10AKMT2A | |
| Hydrochloric Acid SCHEMBL124026 | 0.84 | GAA (0.43) | PDE10AKMT2A | |
| SCHEMBL12742592 | 0.83 | PDE10A (0.41) | PDE10APDE2APDE1BPDE4D | |
| Hydrochloric Acid SCHEMBL124908 | 0.82 | PDE10A (0.41) | PDE10APDE2APDE1BPDE4D | |
| SCHEMBL3322956 | 0.82 | SMO (0.59) | SMORECQLP2RX7NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | SMO 848/4885RECQL 2028/4885PDE10A 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.